These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32930957)

  • 1. Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics.
    Cernea S; Dima L; Correll CU; Manu P
    Drugs; 2020 Nov; 80(17):1763-1781. PubMed ID: 32930957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.
    Hasnain M; Vieweg WV; Hollett B
    Postgrad Med; 2012 Jul; 124(4):154-67. PubMed ID: 22913904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.
    Larsen JR; Vedtofte L; Holst JJ; Oturai P; Kjær A; Correll CU; Vilsbøll T; Fink-Jensen A
    BMJ Open; 2014 Mar; 4(3):e004227. PubMed ID: 24667381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
    Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Svensson CK; Koyuncu K; Schjerning O; Oturai PS; Kjaer A; Nielsen J; Holst JJ; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
    JAMA Psychiatry; 2017 Jul; 74(7):719-728. PubMed ID: 28601891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies.
    Bernardo M; Rico-Villademoros F; García-Rizo C; Rojo R; Gómez-Huelgas R
    Adv Ther; 2021 May; 38(5):2491-2512. PubMed ID: 33826090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
    Svensson CK; Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Koyuncu K; Schjerning O; Nielsen J; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
    Acta Psychiatr Scand; 2019 Jan; 139(1):26-36. PubMed ID: 30374965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
    Mukundan A; Faulkner G; Cohn T; Remington G
    Cochrane Database Syst Rev; 2010 Dec; 2010(12):CD006629. PubMed ID: 21154372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediabetes in patients treated with antipsychotic drugs.
    Manu P; Correll CU; van Winkel R; Wampers M; De Hert M
    J Clin Psychiatry; 2012 Apr; 73(4):460-6. PubMed ID: 22225552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
    Pillinger T; McCutcheon RA; Vano L; Mizuno Y; Arumuham A; Hindley G; Beck K; Natesan S; Efthimiou O; Cipriani A; Howes OD
    Lancet Psychiatry; 2020 Jan; 7(1):64-77. PubMed ID: 31860457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
    Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.
    Reaven GM; Lieberman JA; Sethuraman G; Kraemer H; Davis JM; Blasey C; Tsuang MT; Schatzberg AF
    J Psychiatr Res; 2009 Jul; 43(11):997-1002. PubMed ID: 19268968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotics and glucose homeostasis.
    Bergman RN; Ader M
    J Clin Psychiatry; 2005 Apr; 66(4):504-14. PubMed ID: 15816794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.
    Hasnain M; Fredrickson SK; Vieweg WV
    J Psychopharmacol; 2011 Jun; 25(6):715-21. PubMed ID: 21169390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperglycemia and antipsychotic medications.
    Haupt DW; Newcomer JW
    J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.
    Arslan MS; Tutal E; Sahin M; Karakose M; Ucan B; Ozturk G; Cakal E; Biyikli Gencturk Z; Ozbek M; Delibasi T
    Endocrine; 2017 Feb; 55(2):410-415. PubMed ID: 27743302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.